<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918603</url>
  </required_header>
  <id_info>
    <org_study_id>2018-45</org_study_id>
    <secondary_id>2018-A02297-48</secondary_id>
    <nct_id>NCT03918603</nct_id>
  </id_info>
  <brief_title>Decrease of Lesions Induced by Mechanical Ventilation During ARDS</brief_title>
  <acronym>ECMO-VILI</acronym>
  <official_title>Reduction of Mechanical Ventilation-induced Lesions During ARDS With Multimodal Ultra-protective Ventilation in Combination With ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modification of mechanically ventilated lesions by an ultra-protective multimodal strategy
      compared to a protective strategy in patients with veno-venous ECMO for severe ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the hypothesis is that ECMO, in addition to improving gas exchange, should limit the
      deleterious effects of mechanical ventilation (mechanical ventilation-induced lesions, VILI)
      by drastically reducing minute ventilation (volume reduction). current, Vt, reduction of
      respiratory rate, reduction of mechanical power, reduction of motor pressure or driving
      pressure), adapting the level of PEEP from the data collected by monitoring oesophageal
      pressure and systematically performing positioning sessions in the prone position. This
      ultra-protective strategy could thus promote the restoration of the integrity of the
      alveolo-capillary membrane and thus facilitate the healing of patients. In order to verify
      this concept and, if necessary, to propose a study whose objectives would be more clinical
      (mortality, ventilator-free days), we propose to carry out a study aimed at showing that this
      ultra-protective multimodal strategy reduces the lesions induced by mechanical ventilation
      compared to usual protective ventilatory management during the ECMO as proposed in the EOLIA
      study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammation of biotrauma</measure>
    <time_frame>36months</time_frame>
    <description>Interleukine dosage in pg/mL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>ultra-protective multimodal ventilation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48</description>
  </arm_group>
  <arm_group>
    <arm_group_label>protective ventilation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will received usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ventral décubitus</intervention_name>
    <description>Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus</description>
    <arm_group_label>ultra-protective multimodal ventilation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe ARDS with a PaO2 / FiO2 ratio ≤ 70 mmHg (for at least 2h) measured at PEEP&gt; 10
             cmH2O and FiO2 = 1

          -  OR a severe ARDS with a PaO2 / FiO2&gt; 70 ratio but &lt;100 mmHg with a plateau pressure&gt;
             35 cmH2O and a pH &lt;7.20

        Exclusion Criteria:

          -  Patients with associated hemodynamic failure requiring veno-arterial ECMO

          -  Impossibility of setting up or contraindication to the placement of an esophageal tube

          -  Impossibility of realization of ventral decubitus

          -  Patient to receive corticosteroids during the first 48 hours following venous venous
             ECMO.

          -  Patients assisted by veno-venous ECMO for more than 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie GARRIDO</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Guervilly</last_name>
    <phone>04 91 96 58 42</phone>
    <email>christophe.guervilly@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Sudour</last_name>
    <phone>04 91 38 29 03</phone>
    <email>promotion.interne@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Guervilly</last_name>
      <phone>04 91 96 58 42</phone>
      <phone_ext>+33</phone_ext>
      <email>christophe.guervilly@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Sudour</last_name>
      <phone>04 91 38 29 03</phone>
      <phone_ext>+33</phone_ext>
      <email>patrick.sudour@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Papazian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

